Liquid Biopsy Market Report 2026

Liquid Biopsy Market Overview

• Liquid Biopsy market size has reached to $1.46 billion in 2025 • Expected to grow to $3.11 billion in 2030 at a compound annual growth rate (CAGR) of 16.2% • Growth Driver: Government Funding Driving Growth In The Market For Cancer Detection • Market Trend: Advancements In Noninvasive Genomic Profiling For Solid Tumors Using Ctdna Assays • North America was the largest region in 2025 and Western Europe is the fastest growing region.

The key promising market opportunities in the liquid biopsy market include: • Assays Kits (Segmentation By Product) → Expected gain of $0.85 Billion • Instruments (Segmentation By Product) → Expected gain of $0.44 Billion • Services (Segmentation By Product) → Expected gain of $0.36 Billion

What Is Covered Under Liquid Biopsy Market?

A liquid biopsy is a quick and painless substitute for surgical biopsies that allows medical professionals to learn a lot about a tumor from a small blood sample. A liquid biopsy is a diagnostic test performed on blood to detect the presence of any cancerous cells in the blood. It is used to detect cancer at an early stage. The main product types of liquid biopsy are assay kits, instruments, and services. Assay kits provide the reagents needed to conduct analytical tests for the measurement of specific analysis in industries such as food, cereals and dietary fiber, dairy, analytical laboratories, animal feed and nutrition, biofuels, biotechnology, wine, malting and brewing, and research. The various clinical applications include early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring orthopedics that are used by reference laboratories, hospitals and physician laboratories, and academic and research centers.

What Is The Liquid Biopsy Market Growth Forecast?

The liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $3.11 billion in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to rising demand for precision oncology, increasing adoption in routine cancer screening, expanding applications in recurrence monitoring, growth in oncology diagnostic spending, increasing awareness among clinicians and patients. Major trends in the forecast period include rising adoption of non-invasive cancer diagnostics, increasing use of liquid biopsy for early cancer detection, growing demand for real-time treatment monitoring, expansion of liquid biopsy in personalized oncology, rising clinical acceptance as an alternative to tissue biopsy.

What Is The Driver Of The Liquid Biopsy Market?

Increase in government funding for the advancement of cancer detection is a key driver in the growth of the liquid biopsy market. Government funding for the advancement of cancer detection is primarily attributed to the rising global burden of cancer, the need for early diagnosis to improve treatment outcomes, and the focus on reducing healthcare costs through innovative diagnostic technologies. Government funding helps liquid biopsy by accelerating research and development, supporting clinical trials, and promoting the adoption of advanced, non-invasive diagnostic technologies to improve early cancer detection and personalized treatment strategies. For instance, in October 2024, gov.UK, a UK-based government website, a total of £118 ($150.38) million has been allocated to UK Research and Innovation, with £54 million from the government and £64 ($81.55) million from partners. Thus, increase in government funding for the advancement of cancer detection is driving the growth of the liquid biopsy industry.

How Will The Drivers Impact Growth In The Global Liquid Biopsy Market?

• Rising Prevalence Of Cancer Cases (Low) – During the forecast period, the rising prevalence of cancer cases is expected to become a major growth driver for the liquid biopsy market by 2030. Increasing incidence of various cancers, including lung, breast, colorectal, and prostate cancer, is creating significant demand for early detection and continuous monitoring solutions. Liquid biopsy enables real-time analysis of tumor-derived biomarkers through blood samples, supporting timely diagnosis and improved patient outcomes. Healthcare systems are increasingly focusing on early-stage detection to reduce treatment costs and mortality rates. As cancer burden continues to rise globally, the adoption of liquid biopsy as a complementary or alternative diagnostic tool is expanding rapidly. • Growing Demand For Non-Invasive Diagnostic Techniques (Low) – During the forecast period, the growing demand for non-invasive diagnostic techniques is expected to emerge as a key factor driving the expansion of the liquid biopsy market by 2030. Patients and healthcare providers are increasingly preferring minimally invasive procedures that reduce discomfort, risk of complications, and recovery time compared to traditional tissue biopsies. Liquid biopsy offers advantages such as repeat sampling, faster turnaround time, and improved patient compliance, making it highly suitable for longitudinal disease monitoring. This shift toward non-invasive diagnostics is particularly important in advanced cancer stages where tissue biopsy may be challenging. • Advancements In Genomic And Molecular Diagnostic Technologies (High) – During the forecast period, advancements in genomic and molecular diagnostic technologies are expected to act as a key growth catalyst for the liquid biopsy market by 2030. Continuous innovations in next-generation sequencing (NGS), polymerase chain reaction (PCR), and bioinformatics are enhancing the sensitivity and accuracy of detecting circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers. These technological improvements are enabling more precise therapy selection, treatment monitoring, and recurrence detection. Additionally, increasing integration of artificial intelligence and data analytics in genomic interpretation is accelerating clinical adoption.

How Will The Restraints Impact Growth In The Global Liquid Biopsy Market?

• High Cost Of Liquid Biopsy Tests (Low) – During the forecast period, high cost of liquid biopsy tests is significantly restraining the growth of the liquid biopsy market. The expensive nature of advanced assays, sequencing technologies, and laboratory processing is limiting affordability and reducing adoption, particularly in cost-sensitive healthcare systems and developing regions. • Limited Clinical Validation And Standardization (Low) – During the forecast period, limited clinical validation and standardization are significantly restraining the growth of the liquid biopsy market. Variability in test performance, lack of universally accepted protocols, and insufficient large-scale validation studies are reducing clinician confidence and slowing widespread clinical adoption. • Regulatory And Ethical Challenges (High) – During the forecast period, regulatory and ethical challenges are significantly restraining the growth of the liquid biopsy market. Complex approval pathways, data privacy concerns, and ethical issues related to genetic information handling are increasing compliance burdens and delaying commercialization of liquid biopsy technologies.

Key Players In The Global Liquid Biopsy Market

Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

Global Liquid Biopsy Market Trends and Insights

Major companies operating in the liquid biopsy market are focusing on developing innovative solutions, such as comprehensive circulating tumor DNA (ctDNA) genomic-profiling assays, to accelerate noninvasive cancer profiling, enable faster therapeutic decision-making, and broaden access to precision oncology where tissue is limited or unobtainable. A ctDNA comprehensive genomic-profiling assay analyzes fragments of tumor-derived cell-free DNA circulating in blood to detect somatic small variants, copy-number changes, insertions/deletions, and immuno-oncology signatures (e.g., bTMB and bMSI), offering broader tumor insight without the invasiveness, sampling bias, and longer turnaround time of traditional tissue biopsies. For instance, in November 2023, Illumina Inc., a US–based sequencing and genomics company, launched TruSight Oncology 500 ctDNA v2, a research-use liquid biopsy panel for noninvasive genomic profiling of solid tumors, integrating an expanded hybrid-capture panel with DRAGEN bioinformatics for sequencing 523 biomarkers from low cfDNA input. The assay enriches and detects SVs, CNVs, indels, and immuno-oncology metrics with high analytical performance, offers streamlined workflows with a single hybridization step and <4-day turnaround, and is compatible with NovaSeq systems and upcoming automation. It supports use when tissue is unavailable or delayed, complements tissue testing, and enables broad pan-cancer research and trial screening, providing faster insights, suitability for low-input samples, and easier adoption across distributed lab environments.

What Are Latest Mergers And Acquisitions In The Liquid Biopsy Market?

In February 2024, Veracyte Inc., a US-based diagnostics company, acquired C2i Genomics Inc. for $70 million. With this acquisition, Veracyte is planning to enhance its diagnostics platform with whole-genome minimal residual disease (MRD) capabilities. This acquisition allows Veracyte to utilize C2i's AI-driven technology for improved detection of circulating tumor DNA from blood samples, aiming to expand its cancer care offerings. C2i Genomics Inc. is a US-based company, providing AI-powered liquid biopsy for cancer diagnostics.

What Defines the Liquid Biopsy Market?

The liquid biopsy market includes revenues earned by entities by DNA collection tubes, tests, and reagents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Liquid Biopsy Market Report 2026?

The liquid biopsy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the liquid biopsy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.